Biosafety Directive for Human Immunodeficiency Virus (HIV) and Human T-cell Lymphotropic Virus Type 1 (HTLV-1)

Biosafety Directive for Human Immunodeficiency Virus (HIV) and Human T-cell Lymphotropic Virus Type 1 (HTLV-1) The human immunodeficiency virus (HIV) and the human T-cell lymphotropic virus type 1 (HTLV-1) are examples of RG3 pathogens where the pathogen risk and CL assessments have been revisited by the Agency in conjunction with HIV/HTLV specialists based on current risks associated with activities involving these pathogens. It has been determined that HIV & HTLV-1 can be safely handled at CL2/CL2-Ag with specific additional operational requirements (see Section 4.0). This Biosafety Directive is intended to provide a comprehensive overview of the risk assessment outcomes, subsequent CL decisions, and considerations that have been made for those working with HIV and HTLV-1. The Biosafety Directive for HIV and HTLV-1 is to be used in conjunction with the CBSG. 2019-02-11 Public Health Agency of Canada open-ouvert@tbs-sct.gc.ca Health and Safetypathogenrisk groupshuman immunodeficiency virushivdescriptionrisk factorshuman t-celllymphotropic virustype 1htlv-1containmentlevelrequirementscbsgcontainment zonecontainment levelcldeterminationoperational requirementsactivitiesin vivobiosafetydirectivehumanimmunodeficiencyvirushivt-celltype 1htlv-1 Biosafety Directive for Human Immunodeficiency Virus (HIV) and Human T-cell Lymphotropic Virus Type 1 (HTLV-1)HTML https://www.canada.ca/en/public-health/services/laboratory-biosafety-biosecurity/biosafety-directive-human-immunodeficiency-virus-hiv-human-cell-lymphotropic-virus-type-1-htlv-1.html Biosafety Directive for Human Immunodeficiency Virus (HIV) and Human T-cell Lymphotropic Virus Type 1 (HTLV-1)HTML https://www.canada.ca/fr/sante-publique/services/biosecurite-biosurete-laboratoire/directive-matiere-biosecurite-portant-virus-immunodeficience-humaine-vih-virus-lymphotrope-humain-type-1-htlv-1.html

The human immunodeficiency virus (HIV) and the human T-cell lymphotropic virus type 1 (HTLV-1) are examples of RG3 pathogens where the pathogen risk and CL assessments have been revisited by the Agency in conjunction with HIV/HTLV specialists based on current risks associated with activities involving these pathogens. It has been determined that HIV & HTLV-1 can be safely handled at CL2/CL2-Ag with specific additional operational requirements (see Section 4.0). This Biosafety Directive is intended to provide a comprehensive overview of the risk assessment outcomes, subsequent CL decisions, and considerations that have been made for those working with HIV and HTLV-1. The Biosafety Directive for HIV and HTLV-1 is to be used in conjunction with the CBSG.

Data and Resources

Similar records